Hayakawa Kazuhide, Mishima Kenichi, Hazekawa Mai, Sano Kazunori, Irie Keiichi, Orito Kensuke, Egawa Takashi, Kitamura Yoshihisa, Uchida Naoki, Nishimura Ryoji, Egashira Nobuaki, Iwasaki Katsunori, Fujiwara Michihiro
Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka City, Fukuoka, Japan.
Brain Res. 2008 Jan 10;1188:157-64. doi: 10.1016/j.brainres.2007.09.090. Epub 2007 Oct 12.
Cannabidiol, a non-psychoactive component of cannabis, has been reported to have interactions with Delta(9)-tetrahydrocannabinol (Delta(9)-THC). However, such interactions have not sufficiently been clear and may have important implications for understanding the pharmacological effects of marijuana. In the present study, we investigated whether cannabidiol modulates the pharmacological effects of Delta(9)-THC on locomotor activity, catalepsy-like immobilisation, rectal temperature and spatial memory in the eight-arm radial maze task in mice. In addition, we measured expression level of cannabinoid CB(1) receptor at striatum, cortex, hippocampus and hypothalamus. Delta(9)-THC (1, 3, 6 and 10 mg/kg) induced hypoactivity, catalepsy-like immobilisation and hypothermia in a dose-dependent manner. In addition, Delta(9)-THC (1, 3 and 6 mg/kg) dose-dependently impaired spatial memory in eight-arm radial maze. On the other hand, cannabidiol (1, 3, 10, 25 and 50 mg/kg) did not affect locomotor activity, catalepsy-like immobilisation, rectal temperature and spatial memory on its own. However, higher dose of cannabidiol (10 or 50 mg/kg) exacerbated pharmacological effects of lower dose of Delta(9)-THC, such as hypoactivity, hypothermia and impairment of spatial memory. Moreover, cannabidiol (50 mg/kg) with Delta(9)-THC (1 mg/kg) enhanced the expression level of CB(1) receptor expression in hippocampus and hypothalamus. Cannabidiol potentiated pharmacological effects of Delta(9)-THC via CB(1) receptor-dependent mechanism. These findings may contribute in setting the basis for interaction of cannabinoids and to find a cannabinoid mechanism in central nervous system.
大麻二酚是大麻中的一种非精神活性成分,据报道它与Δ⁹-四氢大麻酚(Δ⁹-THC)存在相互作用。然而,这种相互作用尚未完全明确,可能对理解大麻的药理作用具有重要意义。在本研究中,我们调查了大麻二酚是否会调节Δ⁹-THC对小鼠运动活动、僵住样固定、直肠温度以及八臂放射状迷宫任务中的空间记忆的药理作用。此外,我们测量了纹状体、皮层、海马体和下丘脑处大麻素CB₁受体的表达水平。Δ⁹-THC(1、3、6和10毫克/千克)以剂量依赖性方式诱导活动减少、僵住样固定和体温过低。此外,Δ⁹-THC(1、3和6毫克/千克)在八臂放射状迷宫中剂量依赖性地损害空间记忆。另一方面,大麻二酚(1、3、10、25和50毫克/千克)自身对运动活动、僵住样固定、直肠温度和空间记忆没有影响。然而,较高剂量的大麻二酚(10或50毫克/千克)会加剧较低剂量Δ⁹-THC的药理作用,如活动减少、体温过低和空间记忆损害。此外,大麻二酚(50毫克/千克)与Δ⁹-THC(1毫克/千克)一起可增强海马体和下丘脑处CB₁受体的表达水平。大麻二酚通过CB₁受体依赖性机制增强了Δ⁹-THC的药理作用。这些发现可能有助于为大麻素之间的相互作用奠定基础,并在中枢神经系统中找到一种大麻素机制。